UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 23, 2022



OPTION CARE HEALTH, INC.

(Exact name of registrant as specified in its charter)

001-11993 (Commission File Number) <u>05-0489664</u> (IRS Employer Identification Number)

3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 (Address of principal executive offices)

(312) 940-2443

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Securities registered pursuant to Section 12(b) of the Act:

Delaware

(State or other jurisdiction of incorporation)

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	OPCH	Nasdaq Global Select Market

Item 2.02. Results of Operations and Financial Condition.

On February 23, 2022, Option Care Health, Inc. issued a press release reporting its fourth quarter and full-year 2021 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	Press release dated February 23, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Option Care Health, Inc.

Date: February 23, 2022

By: /s/ Michael Shapiro

Michael Shapiro Chief Financial Officer

Exhibit 99.1



OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021 AND ANNOUNCES TWO ADDITIONAL ACQUISITIONS

BANNOCKBURN, IL., February 23, 2022 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2021.

The Company also announced that it acquired Wasatch Infusion LLC ("Wasatch"), an infusion center operator based in Salt Lake City, Utah, in December and has also entered into a definitive agreement to acquire Specialty Pharmacy Nursing Network, Inc. ("SPNN"), which it expects to complete in 2022.

Fourth Quarter 2021 Financial Highlights

- Net revenue of \$927.2 million, up 15.2% compared to \$804.7 million in the fourth quarter of 2020
- Gross profit of \$212.2 million, or 22.9% of revenue, up 15.5% compared to \$183.8 million, or 22.8% of revenue, in the fourth quarter of 2020
- Net income of \$75.5 million, or \$0.42 earnings per share inclusive of a one-time benefit from the elimination of the Company's valuation allowance on deferred tax assets of \$30.4 million or \$0.17 per share, compared to net income of \$17.8 million, or \$0.10 earnings per share, in the fourth quarter of 2020
- Adjusted EBITDA of \$86.8 million, up 28.3% compared to \$67.7 million in the fourth quarter of 2020
- Cash flow from operations of \$65.3 million, and cash balances of \$119.4 million at the end of the fourth quarter
- Acquired Infinity Infusion Nursing, LLC and Wasatch for \$50.0 million and \$17.8 million, respectively, financed through cash balances on hand

Full Year 2021 Financial Highlights

- Net revenue of \$3,438.6 million up 13.4% compared to \$3,032.6 million in the full year 2020
- Gross profit of \$779.6 million, or 22.7% of revenue, up 14.2% compared to \$682.3 million, or 22.5% of revenue, in full year 2020
- Net income of \$139.9 million, or \$0.78 earnings per share, compared to net loss of \$8.1 million, or \$0.04 loss per share, in full year 2020
- Adjusted EBITDA of \$289.8 million, up 30.7% compared to \$221.7 million in full year 2020
- Cash flow from operations of \$208.6 million, up 63.7% compared to \$127.4 million in full year 2020

John C. Rademacher, Chief Executive Officer, commented, "The entire Option Care Health team continues to execute in an ongoing challenging environment. With the patient at the center of everything we do, Option Care Health served over a quarter of a million patients in 2021 despite the ongoing pandemic situation. We are proud of the results we have generated as well as the many investments we continue to make to drive future growth."

Full Year 2022 Financial Guidance

For the full year 2022, Option Care Health expects to deliver the following financial results:

- Net revenue of \$3.65 billion to \$3.85 billion
- Adjusted EBITDA of \$310 million to \$330 million
- Cash flow from operations of at least \$230 million

The financial expectations do not include any impact from the acquisition of SPNN as it has not yet been completed.

Conference Call

The conference call can be accessed by dialing (866) 360-3136 for U.S. participants or (602) 563-8603 for international participants, and referencing conference ID 7156207; or via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,000 teammates, including approximately 4,300 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at <u>OptionCareHealth.com</u>.

Investor Contacts

Mike Shapiro Chief Financial Officer T: (312) 940-2538 <u>mike.shapiro@optioncare.com</u>

Bob East, Asher Dewhurst, Jordan Kohnstam Westwicke T: (413) 213-0500 <u>optioncarehealth@westwicke.com</u>

Forward-Looking Statements - Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; and (iv) the loss of one or more key payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long–lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.

OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)

		December 31, 2021 2020				
		2021				
ASSETS			-			
CURRENT ASSETS:						
Cash and cash equivalents	\$	119,423	\$	99,265		
Accounts receivable, net		338,242		328,340		
Inventories		183,095		158,601		
Prepaid expenses and other current assets		69,496		70,806		
Total current assets		710,256		657,012		
NONCURRENT ASSETS:						
Property and equipment, net		111,535		121,149		
Intangible assets, net		21,433		23,429		
Referral sources		344,587		327,623		
Goodwill		1,477,564		1,428,610		
Other noncurrent assets		125,543		89,616		
Total noncurrent assets		2,080,662		1,990,427		
TOTAL ASSETS	\$	2,790,918	\$	2,647,439		
LIABILITIES AND STOCKHOLDERS' EQUITY						
CURRENT LIABILITIES:						
Accounts payable	\$	279,246	\$	282,913		
Other current liabilities	•	180,449	*	151,110		
Total current liabilities		459,695		434,023		
NONCURRENT LIABILITIES:						
Long-term debt, net of discount, deferred financing costs and current portion		1,059,900		1,115,103		
Other noncurrent liabilities		95,437		82,589		
Total noncurrent liabilities		1,155,337	-	1,197,692		
Total liabilities		1,615,032		1,631,715		
		1,010,002		1,001,710		
STOCKHOLDERS' EQUITY		1,175,886		1,015,724		
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$	2,790,918	\$	2,647,439		

OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

		Three Months Ended December 31,				Year Ended December 31,				
	2021			2020		2021		2020		
NET REVENUE	\$	927,194	\$	804,713	\$	3,438,640	\$	3,032,610		
COST OF REVENUE		714,997		620,951		2,659,034		2,350,346		
GROSS PROFIT		212,197		183,762		779,606		682,264		
OPERATING COSTS AND EXPENSES:										
Selling, general and administrative expenses		136,777		123,001		525,707		500,199		
Depreciation and amortization expense		14,648		16,418		63,058		71,310		
Total operating expenses		151,425		139,419		588,765		571,509		
OPERATING INCOME		60,772		44,343		190,841		110,755		
OTHER INCOME (EXPENSE):										
Interest expense, net		(14,286)		(23,668)		(67,003)		(107,770)		
Other, net		481		(2,270)		(7,344)		(8,228)		
Total other expense		(13,805)		(25,938)		(74,347)		(115,998)		
INCOME (LOSS) BEFORE INCOME TAXES		46,967		18,405		116,494		(5,243)		
INCOME TAX (BENEFIT) EXPENSE		(28,500)		566		(23,404)		2,833		
NET INCOME (LOSS)	\$	75,467	\$	17,839	\$	139,898	\$	(8,076)		
Earnings (loss) per share, basic	\$	0.42	\$	0.10	\$	0.78	\$	(0.04)		
Earnings (loss) per share, diluted	\$	0.41	\$	0.10	\$	0.77	\$	(0.04)		

OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)

CASH FLOWS FROM OPERATING ACTIVITIES: 139,898 Net income (loss) 139,898 Adjustments to reconcile net income (loss) to net cash provided by operations: 0 Depreciation and amortization expense 68,804 Paid-in-kind interest capitalized as principal - Other non-cash adjustments 11,237 Changes in operating assets and liabilities: (4,273) Accounts receivable, net (4,273) Inventories (22,700) Accounts receivable, net (10,381) Other 25,984 Net cash provided by operating activities 208,569 CASH FLOWS FROM INVESTING ACTIVITIES: - Acquisition of property and equipment (25,632) Other investing cash flows - Business acquisitions, net of cash acquired (85,099) Net cash used in investing activities (111,541) CASH FLOWS FROM FINANCING ACTIVITIES: - Proceeds from debt 85,136 Retirement of debt obligations (910,345) Net proceeds from debt (76,870) Net proceeds from dows - Other financing cash flows (11,322) <		Year En Decembe	
Net income (loss) 139,098 Adjustments to reconcile net income (loss) to net cash provided by operations: - Depreciation and amortization expense 68,004 - Paid-in-kind interest capitalized as principal - - Other non-cash adjustments 11,237 - Accounts receivable, net (4,273) - Inventories (22,700) (c Accounts receivable, net (10,381) - Other 25,934 - Other 208,569 11 CASH FLOWS FROM INVESTING ACTIVITIES: - - Acquisition of property and equipment (25,632) (C Other investing cash flows - - Business acquisitions, net of cash acquired (85,909) - Net cash used in investing activities (111,541) (C CASH FLOWS FROM FINANCING ACTIVITIES: - - Proceeds from debt 855,136 - Retirement of debt obligations (910,345) (11,329) Other investing costs (10,339) - 1 Defered financing costs (10,339) <t< th=""><th></th><th>2021</th><th>2020</th></t<>		2021	2020
Adjustments to reconcile net income (loss) to net cash provided by operations: 0 Depreciation and amortization expense 68,004 Paid-in-kind interest capitalized as principal Other non-cash adjustments 11,237 Changes in operating assets and liabilities: (4,273) Accounts receivable, net (4,273) Inventories (22,700) (Accounts payable (10,381) Other 25,984 Net cash provided by operating activities 208,569 CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of property and equipment (25,632) (1 Other investing cash flows Business acquisitions, net of cash acquired (85,909) Net cash used in investing activities (111,541) (2 CASH FLOWS FROM FINANCING ACTIVITIES: 1 Proceeds from debt 855,136 Retirement of debt obligations 1 Deferred financing costs (11,322) (1 Net cash lows 1 Deferred financing costs (11,322) (1	CASH FLOWS FROM OPERATING ACTIVITIES:		
Depreciation and amortization expense68,804Paid-in-kind interest capitalized as principal—Other non-cash adjustments11,237Changes in operating assets and liabilities:(4,273)Accounts receivable, net(4,273)Inventories(22,700)Accounts payable(10,381)Other25,984Net cash provided by operating activities208,569CASH FLOWS FROM INVESTING ACTIVITIES:—Acquisition of property and equipment(25,632)Other investing cash flows—Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:—CASH FLOWS FROM FINANCING ACTIVITIES:—Acquisitions, net of cash acquired(85,909)Net cash used in investing activities—CASH FLOWS FROM FINANCING ACTIVITIES:—Proceeds from debt855,136Retirement of debt obligations—Net proceeds from issuance of common stock—Deferred financing costs(10,339)Other financing costs(10,339)Other financing costs(11,322)Net cash (used in) financing activities(20,158)Net cosh used in productives(20,158)Cash and cash equivalents - beginning of the period99,265	Net income (loss)	139,898	(8,076)
Paid-in-kind interest capitalized as principal—Other non-cash adjustments11,237Changes in operating assets and liabilities:	Adjustments to reconcile net income (loss) to net cash provided by operations:		
Other non-cash adjustments11,237Changes in operating assets and liabilities:Accounts receivable, net(4,273)Inventories(22,700)(4,273)Inventories(22,700)(10,381)Other25,984Net cash provided by operating activitiesCASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(25,632)(Cher investing cash flows—Business acquisitions, net of cash acquired(85,909)Net cash used in investing activitiesCASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debtRetirement of debt obligationsProceeds from debtBesting cash flows—1Deferred financing costs(10,339)Other financing cash flows—111,222(Correcteds from signance of common stock—111,221(Correctash flows(11,322)(Correctash Lancing costs(11,322)(Correctash Lancing costs(11,322)(Correctash Lancing costities(26,700)(27,701)(27,702)(28, 100, 28)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)(20, 158)<	Depreciation and amortization expense	68,804	77,896
Changes in operating assets and liabilities: (4,273) Accounts receivable, net (4,273) Inventories (22,700) Accounts payable (10,381) Other 25,884 Net cash provided by operating activities 208,569 CASH FLOWS FROM INVESTING ACTIVITIES: 208,569 Acquisition of property and equipment (25,632) Other investing cash flows — Business acquisitions, net of cash acquired (85,909) Net cash used in investing activities (111,541) CASH FLOWS FROM FINANCING ACTIVITIES: — Proceeds from debt 855,136 Retirement of debt obligations (910,345) (11 Net cash (used in financing activities — 1 Deferred financing costs (10,339) (11,322) (C Net cash (used in) financing activities (76,870) (C (C Net cash used in infancing activities (76,870) (C (C Action of the period 99,265 4	Paid-in-kind interest capitalized as principal		7,525
Accounts receivable, net(4,273)Inventories(22,700)Accounts payable(10,381)Other25,984Net cash provided by operating activities208,569CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(25,632)Other investing cash flows-Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations-1Deferred financing costsOther financing costs(10,339)Other financing cost (10,339)(11,322)Other financing activities(76,870)Other financing activities(20,632)Cash and cash equivalents - beginning of the period99,265	Other non-cash adjustments	11,237	42,917
Inventories(22,700)Accounts payable(10,381)Other25,984Net cash provided by operating activities208,569CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(25,632)Other investing cash flowsBusiness acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock1Deferred financing costs(11,322)Other financing cost flows(11,322)Net cash used in financing activities(27,670)(0)Net cash used in financing activities(27,670)Other financing costs(20,0158)Cash and cash equivalents - beginning of the period99,265	Changes in operating assets and liabilities:		
Accounts payable(10,381)Other25,984Net cash provided by operating activities208,569It208,569CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of property and equipment(25,632)Other investing cash flows—Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(11,541)CASH FLOWS FROM FINANCING ACTIVITIES:—Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock—1Deferred financing cash flows—0(11,322)(11,322)(11,322)Net cash (used in financing activities(76,870)0(11,322)Net cash (used in financing activities(10,339)0(11,322)Net cash (used in financing activities(76,870)(0(11,322)Net cash used in financing of the period99,265	Accounts receivable, net	(4,273)	(3,924)
Other 25,984 Net cash provided by operating activities 208,569 CASH FLOWS FROM INVESTING ACTIVITIES: (25,632) Acquisition of property and equipment (25,632) Other investing cash flows	Inventories	(22,700)	(42,725)
Net cash provided by operating activities 208,569 11 CASH FLOWS FROM INVESTING ACTIVITIES: (25,632) (2 Acquisition of property and equipment (25,632) (2 Other investing cash flows	Accounts payable	(10,381)	59,215
CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of property and equipment (25,632) Other investing cash flows — Business acquisitions, net of cash acquired (85,909) Net cash used in investing activities (111,541) CASH FLOWS FROM FINANCING ACTIVITIES:	Other	25,984	(5,436)
Acquisition of property and equipment(25,632)(2Other investing cash flows-Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock-1Deferred financing costs(11,322)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	Net cash provided by operating activities	208,569	127,392
Acquisition of property and equipment(25,632)(2Other investing cash flows-Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock-1Deferred financing costs(11,322)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	CASH FLOWS FROM INVESTING ACTIVITIES:		
Other investing cash flows—Business acquisitions, net of cash acquired(85,909)Net cash used in investing activities(111,541)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock—Deferred financing costs(11,322)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	Acquisition of property and equipment	(25.632)	(26,875)
Business acquisitions, net of cash acquired (85,909) Net cash used in investing activities (111,541) CASH FLOWS FROM FINANCING ACTIVITIES: 855,136 Proceeds from debt 855,136 Retirement of debt obligations (910,345) Net proceeds from issuance of common stock — Deferred financing costs (10,339) Other financing cash flows (11,322) Net cash (used in) financing activities (76,870) NET INCREASE IN CASH AND CASH EQUIVALENTS 20,158 Cash and cash equivalents - beginning of the period 99,265			541
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from debt855,136Retirement of debt obligations(910,345)Net proceeds from issuance of common stock—Deferred financing costs(10,339)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	•	(85,909)	_
Proceeds from debt855,136Retirement of debt obligations(910,345)(11Net proceeds from issuance of common stock—1Deferred financing costs(10,339)(11,322)(11,322)Other financing cash flows(11,322)(11,322)(11,322)Net cash (used in) financing activities(76,870)(11,322)NET INCREASE IN CASH AND CASH EQUIVALENTS20,1581Cash and cash equivalents - beginning of the period99,2650	· ·	(111,541)	(26,334)
Proceeds from debt855,136Retirement of debt obligations(910,345)(11)Net proceeds from issuance of common stock—1Deferred financing costs(10,339)(11)Other financing cash flows(11,322)(11)Net cash (used in) financing activities(76,870)(11)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158(11)Cash and cash equivalents - beginning of the period99,265(11)	CASH FLOWS FROM FINANCING ACTIVITIES:		
Retirement of debt obligations(910,345)(11)Net proceeds from issuance of common stock1Deferred financing costs(10,339)Other financing cash flows(11,322)(1)Net cash (used in) financing activities(76,870)(1)NET INCREASE IN CASH AND CASH EQUIVALENTS20,1581Cash and cash equivalents - beginning of the period99,2650	Proceeds from debt	855.136	_
Net proceeds from issuance of common stock—1Deferred financing costs(10,339)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	Retirement of debt obligations		(174,000)
Deferred financing costs(10,339)Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265		_	118,934
Other financing cash flows(11,322)Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265	•	(10,339)	(149)
Net cash (used in) financing activities(76,870)NET INCREASE IN CASH AND CASH EQUIVALENTS20,158Cash and cash equivalents - beginning of the period99,265		(11,322)	(13,634)
NET INCREASE IN CASH AND CASH EQUIVALENTS 20,158 Cash and cash equivalents - beginning of the period 99,265		(76.870)	(68,849)
Cash and cash equivalents - beginning of the period 99,265			32,209
	·		67,056
CASH AND CASH EQUIVALENTS - END OF PERIOD 119,423	CASH AND CASH EQUIVALENTS - END OF PERIOD	119,423	99,265

OPTION CARE HEALTH, INC. QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS) (UNAUDITED)

	Three Months Ended December 31,			Year Ended December 31,				
		2021		2020		2021		2020
Consolidated net income (loss)	\$	75,467	\$	17,839	\$	139,898	\$	(8,076)
Interest expense, net		14,286		23,668		67,003		107,770
Income tax (benefit) expense		(28,500)		566		(23,404)		2,833
Depreciation and amortization expense		15,984		17,842		68,804		77,896
Consolidated EBITDA		77,237		59,915		252,301	-	180,423
EBITDA adjustments								
Stock-based incentive compensation		3,329		332		9,575		2,920
Loss on extinguishment of debt		984		3,196		13,387		11,545
Restructuring, acquisition, integration and other		5,200		4,208		14,543		26,788
Consolidated adjusted EBITDA	\$	86,750	\$	67,651	\$	289,806	\$	221,676